Marketing communications agency Influential has snapped up briefs to provide public relations support to two UK life science spin-outs, both of which have grown out of leading Russell Group universities.
The agency, which has offices in Manchester and Liverpool, is working with University of Bristol spin-out Rosa Biotech, which has a vision to provide patients and clinicians with the benefits of early diagnosis of a broad spectrum of diseases by combining the power of protein design and machine learning. The company is initially targeting the early identification of non-alcoholic fatty liver disease (NAFL).
Influential has also been appointed to work with ReNewVax, a University of Liverpool spin-out company co-founded by Dr Marie Yang and Prof Aras Kadioglu. The company was created through seed funding in 2022, awarded by Innovate ICURe follow on funding and the University of Liverpool’s Enterprise Investment Fund.
ReNewVax has a vaccine development platform with the potential to target a variety of diseases, beginning with a pneumococcal vaccine for use around the world.
Chris Hulme, director at Influential, said: “Rapidly scaling businesses have a dynamism that makes them very attractive to work for and researchers tackling unmet medical needs make for compelling stories. We have a great deal of experience in generating profile and engagement that supports attracting investment and bringing game changing drugs and treatments to improve patient outcomes.
“ReNewVax and Rosa Biotech are two highly impressive companies and representative of the world class science base we still have in UK.”
Influential also acts for the Sci-Tech Daresbury campus and iiCON, a world-leading centre for infection innovation and R&D, whose partners include the Liverpool School of Tropical Medicine, Liverpool University Hospitals NHS Foundation Trust, Unilever UK, the University of Liverpool, Evotec and Infex Therapeutics, based at Alderley Park, Cheshire.
